Table II.
The prognostic influence of PTPRA in SCC.
| Prognostic parameter | Univariate analysis
|
Multivariate analysis
|
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| PTPRA (high vs. low) | 2.271 | 1.284–4.018 | 0.005 | 2.306 | 1.189–4.469 | 0.014 |
| Age (>65 vs. ≤65) | 2.648 | 1.344–5.216 | 0.005 | 2.895 | 1.430–5.859 | 0.003 |
| Sex (female vs. male) | 0.578 | 0.204–1.644 | 0.305 | |||
| Tumor size, cm (>5 vs. ≤5) | 1.209 | 0.633–2.309 | 0.566 | |||
| Tumor location (upper vs. lower) | 0.746 | 0.393–1.416 | 0.370 | |||
| TNM stage (T1 vs. T2 vs. T3) | 1.411 | 0.889–2.238 | 0.143 | |||
| Lymph node metastasis (present vs. absent) | 1.941 | 1.008–3.737 | 0.048 | 1.229 | 0.516–2.921 | 0.6412 |
| Clinical stage | 1.804 | 1.175–2.768 | 0.007 | 1.239 | 0.451–3.406 | 0.6778 |
HR, hazard ratio; CI, confidence interval. The bold number represents the P-value with significant differences.